📰 Nasdaq Trml News
Nasdaq Trml News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Trml. Real-time updates on events, politics, business and more.
April 23, 2024
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has earned an average recommendation of “Buy” from the six brokerages that are presently covering the stock, Marketbeat.com reports. Six analysts have rated the stock with a buy rating. The average 12-month price objective among analysts that have updated their coverage on the stock in the last […]
February 20, 2024
Shares of Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) traded down 7.8% during trading on Tuesday . The stock traded as low as $38.61 and last traded at $39.33. 64,967 shares were traded during mid-day trading, a decline of 73% from the average session volume of 238,561 shares. The stock had previously closed at […]
January 30, 2024
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report)’s stock price rose 3.5% during mid-day trading on Tuesday . The stock traded as high as $38.29 and last traded at $37.80. Approximately 11,465 shares traded hands during trading, a decline of 95% from the average daily volume of 211,499 shares. The stock had previously closed at […]
January 25, 2024
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report)’s share price gapped up prior to trading on Thursday . The stock had previously closed at $36.01, but opened at $37.60. Tourmaline Bio shares last traded at $37.47, with a volume of 329,462 shares traded. Wall Street Analysts Forecast Growth TRML has been the subject of a […]
January 23, 2024
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) hit a new 52-week high during mid-day trading on Tuesday . The company traded as high as $35.37 and last traded at $35.30, with a volume of 16661 shares changing hands. The stock had previously closed at $34.57. Wall Street Analysts Forecast Growth A number of brokerages […]
December 10, 2023
Leerink Partnrs reiterated their outperform rating on shares of Tourmaline Bio (NASDAQ:TRML – Free Report) in a research report released on Thursday, PriceTargets.com reports. Leerink Partnrs also issued estimates for Tourmaline Bio’s FY2026 earnings at ($4.00) EPS. A number of other research firms also recently weighed in on TRML. HC Wainwright reaffirmed a buy rating […]
December 8, 2023
Tourmaline Bio, Inc. (NASDAQ:TRML – Free Report) – Analysts at Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for Tourmaline Bio in a research note issued to investors on Thursday, December 7th. Leerink Partnrs analyst T. Smith expects that the company will post earnings of ($4.00) per share for the year. Leerink Partnrs […]
November 21, 2023
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) Director Parvinder Thiara bought 1,000 shares of Tourmaline Bio stock in a transaction dated Friday, November 17th. The stock was purchased at an average price of $17.31 per share, with a total value of $17,310.00. Following the purchase, the director now directly owns 83,782 shares in the […]
November 21, 2023
Truist Financial initiated coverage on shares of Tourmaline Bio (NASDAQ:TRML – Free Report) in a research note issued to investors on Friday morning, MarketBeat reports. The firm issued a buy rating and a $43.00 target price on the stock. TRML has been the topic of several other reports. Piper Sandler assumed coverage on shares of […]
November 17, 2023
Analysts at Truist Financial began coverage on shares of Tourmaline Bio (NASDAQ:TRML – Get Free Report) in a report released on Friday, Marketbeat.com reports. The brokerage set a “buy” rating and a $43.00 price target on the stock. Truist Financial’s target price indicates a potential upside of 160.92% from the company’s previous close. TRML has […]